Responding to a GLP and GCP laboratory inspection report

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has provided standardized guidance for laboratories responding to inspection deficiencies under the Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) frameworks. This document serves as a universal protocol for all regulated facilities rather than a report for a single company. The guidance outlines how to address findings categorized as Critical, Major, or Other. Regulated entities are required to provide clear, concise responses within the provided inspection report. Key actions include performing a comprehensive root cause analysis and assessing the systemic impact of any deficiency across the entire organization, rather than just correcting individual errors. Organizations must commit to realistic timelines and implement interim controls if remediation takes significant time. A central component of the response is the Corrective and Preventive Action (CAPA) plan. Senior management is responsible for dedicating sufficient resources to ensure all remedial actions are completed by the agreed-upon dates. Failure to meet these commitments may result in deficiency findings being upgraded to a more severe status during follow-up inspections. Additionally, facilities must proactively notify the MHRA regarding any significant organizational or facility changes. This structured approach is designed to streamline the compliance decision-making process and ensure public and environmental safety.